Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects.

Trial Profile

Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Planned end date changed from 1 Sep 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top